Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Oude Lashof A:

Search results

Items: 1 to 20 of 46

1.

Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort.

HIV Med. 2017 Dec 1. doi: 10.1111/hiv.12570. [Epub ahead of print]

PMID:
29194939
2.

Global phylogenetic analysis of Escherichia coli and plasmids carrying the mcr-1 gene indicates bacterial diversity but plasmid restriction.

Matamoros S, van Hattem JM, Arcilla MS, Willemse N, Melles DC, Penders J, Vinh TN, Thi Hoa N; COMBAT consortium, de Jong MD, Schultsz C.

Sci Rep. 2017 Nov 10;7(1):15364. doi: 10.1038/s41598-017-15539-7.

3.

Travel-related acquisition of diarrhoeagenic bacteria, enteral viruses and parasites in a prospective cohort of 98 Dutch travellers.

van Hattem JM, Arcilla MS, Grobusch MP, Bart A, Bootsma MC, van Genderen PJ, van Gool T, Goorhuis A, van Hellemond JJ, Molenkamp R, Molhoek N, Oude Lashof AM, Stobberingh EE, de Wever B, Verbrugh HA, Melles DC, Penders J, Schultsz C, de Jong MD.

Travel Med Infect Dis. 2017 Sep;19:33-36. doi: 10.1016/j.tmaid.2017.08.003. Epub 2017 Aug 24.

4.

Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.

Havenith T, Burger D, Visschers MJ, Schippers J, Oude Lashof A.

Ther Drug Monit. 2017 Apr;39(2):91-92. doi: 10.1097/FTD.0000000000000386.

PMID:
28230617
5.

Detection of the plasmid-mediated colistin-resistance gene mcr-1 in faecal metagenomes of Dutch travellers.

von Wintersdorff CJ, Wolffs PF, van Niekerk JM, Beuken E, van Alphen LB, Stobberingh EE, Oude Lashof AM, Hoebe CJ, Savelkoul PH, Penders J.

J Antimicrob Chemother. 2016 Dec;71(12):3416-3419. Epub 2016 Aug 23.

PMID:
27559117
6.

Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers.

van Hattem JM, Arcilla MS, Bootsma MC, van Genderen PJ, Goorhuis A, Grobusch MP, Molhoek N, Oude Lashof AM, Schultsz C, Stobberingh EE, Verbrugh HA, de Jong MD, Melles DC, Penders J.

Future Microbiol. 2016 Jul;11:857-64. doi: 10.2217/fmb.16.18. Epub 2016 Jun 30.

7.

Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.

Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B; ATHENA National Observational Cohort Study.

HIV Med. 2016 Sep;17(8):571-80. doi: 10.1111/hiv.12355. Epub 2016 Feb 4.

PMID:
26842457
8.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
9.

Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

Op de Coul EL, van Sighem A, Brinkman K, van Benthem BH, van der Ende ME, Geerlings S, Reiss P; ATHENA National Observational HIV Cohort.

BMJ Open. 2016 Jan 4;6(1):e009688. doi: 10.1136/bmjopen-2015-009688.

10.

Diagnosis and management of aspergillosis in the Netherlands: a national survey.

Lestrade PP, Meis JF, Arends JP, van der Beek MT, de Brauwer E, van Dijk K, de Greeff SC, Haas PJ, Hodiamont CJ, Kuijper EJ, Leenstra T, Muller AE, Oude Lashof AM, Rijnders BJ, Roelofsen E, Rozemeijer W, Tersmette M, Terveer EM, Verduin CM, Wolfhagen MJ, Melchers WJ, Verweij PE.

Mycoses. 2016 Feb;59(2):101-7. doi: 10.1111/myc.12440. Epub 2015 Dec 9.

PMID:
26648179
11.

Risk stratification by abbMEDS and CURB-65 in relation to treatment and clinical disposition of the septic patient at the emergency department: a cohort study.

Roest AA, Tegtmeier J, Heyligen JJ, Duijst J, Peeters A, Borggreve HF, Oude Lashof AM, Stehouwer CD, Stassen PM.

BMC Emerg Med. 2015 Oct 13;15:29. doi: 10.1186/s12873-015-0056-z.

12.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
13.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

14.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
15.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

16.

Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.

Gras L, de Wolf F, Smit C, Prins M, van der Meer JT, Vanhommerig JW, Zwinderman AH, Schinkel J, Geskus RB; ATHENA national observational cohort and the MOSAIC study.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42. doi: 10.1097/QAI.0000000000000514.

PMID:
25559595
17.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group.

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
18.

High rates of antimicrobial drug resistance gene acquisition after international travel, The Netherlands.

von Wintersdorff CJ, Penders J, Stobberingh EE, Oude Lashof AM, Hoebe CJ, Savelkoul PH, Wolffs PF.

Emerg Infect Dis. 2014 Apr;20(4):649-57. doi: 10.3201/eid.2004.131718.

19.

Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?

Gras L, Geskus RB, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort.

PLoS One. 2013 May 27;8(5):e64437. doi: 10.1371/journal.pone.0064437. Print 2013.

20.

Does a patient-level quantitative review of randomized trials on the outcomes in candidemia and invasive candidiasis need to include all patients?

Oude Lashof AM, Vogelaers D.

Clin Infect Dis. 2013 May;56(10):1514-5. doi: 10.1093/cid/cit061. Epub 2013 Feb 5. No abstract available.

PMID:
23386635

Supplemental Content

Loading ...
Support Center